Company

Nitrome Biosciences, Inc.

Brisbane-based biotech developing antibody candidates for neurodegenerative diseases using its proprietary NITROME Platform.

About

Founded in 2017 and headquartered in Brisbane, US, Nitrome Biosciences, Inc. develops antibody candidates for neurodegenerative diseases such as Parkinson's Disease, drawing on its proprietary NITROME Platform to identify nitrases and their nitro-substrates. Irene Griswold-Prenner is both CEO and founder. Its most recent round was a Series A in April 2022, raising USD 7.00 mn led by Bristol-Myers Squibb Company, and it has completed 8 deals in total. Its clients include healthcare providers, research institutions and pharmaceutical companies in North America, Europe and Asia.

4Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in